Meloxicam cost saving over piroxicam and diclofenac in OA

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1385, 2003-01, pp. : 6-6

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Meloxicam cost saving over piroxicam and diclofenac in OA

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 410, 2003-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Modelling Therapeutic Strategies in the Treatment of Osteoarthritis: An Economic Evaluation of Meloxicam Versus Diclofenac and Piroxicam

By Tavakoli M.

PharmacoEconomics, Vol. 21, Iss. 6, 2003-01 ,pp. : 443-454

Adis International

Access to resources Recommend Favorite

Hylan-G-F-20 for OA of the knee cost saving in US managed care

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 360, 2002-01 ,pp. : 3-4

Adis International

Access to resources Recommend Favorite

Hylan-G-F-20 for OA of the knee cost saving in US managed care

Inpharma, Vol. 1, Iss. 1334, 2002-01 ,pp. : 5-6

Adis International

Access to resources Recommend Favorite

Fondaparinux cost saving over enoxaparin for VTE prophylaxis

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 457, 2004-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite